Rahul Ballal, PhD
Rahul joined the Vaderis board in October 2022 and is currently the Chief Executive Officer at Mediar Therapeutics. He is a biopharmaceutical executive with more than 15 years of experience in business development, strategic transactions, and company financing. Rahul previously served as Imara’s (IMRA) president and chief executive officer. Prior to this role, he served as chief business officer of Northern Biologics and as an entrepreneur-in-residence at Versant Ventures. Previously, Dr. Ballal was vice president of business development at Flexion Therapeutics (FLXN). Additionally, Rahul currently serves on the Board of Directors of Agios (AGIO), and Enliven Therapeutics (ELVN). Rahul holds a Ph.D. in biochemistry from Georgetown University, an M.S. in bioinformatics from Johns Hopkins University and a B.S. in biology from Brown University.